One of the most significant challenges that cell and advanced therapy (CAT) companies can face at every stage of their growth is decisions related to financing to keep their operations well-funded at the most advantageous terms. From the very earliest funding stages often involving personal investments by company principals or “angel” investors to decisions related to venture capital investment, public offerings or licensing or acquisition strategies, multiple factors must often be considered.
How do companies identify and attract the right investors for their technology platform and target indications? How far advanced and “de-risked” must their technology be to attract investors at different stages? How much equity and control will investors have? How might changing economic conditions affect future financing options?
Decisions related to financing can have a profound impact on a CAT company’s chances for success. To highlight some of the most important financing challenges and opportunities for CAT companies, Invetech reached out to several experienced leaders in investment and corporate finance in the sector for perspectives and insights, including: